Oncology Institute, Inc. (TOI) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Care Facilities CIK: 0001799191

Market Cap 315.37 Mn

P/E -5.70

P/S 0.63

Div. Yield 0.00

ROIC (Qtr) -0.57

Total Debt (Qtr) 77.40 Mn

Revenue Growth (1y) (Qtr) 41.58

Add ratio to table...

About

Oncology Institute, Inc., or TOI, is a prominent player in the healthcare industry, specifically in the field of oncology. The company is known for its value-based approach, which aims to deliver better patient outcomes at a lower cost. This approach differentiates TOI from its competitors, making it a leading entity in the sector. TOI's primary business activities revolve around managing community-based oncology practices across 15 markets and five states in the United States. The company provides a range of medical oncology services, including...

Oncology Institute, Inc., or TOI, is a prominent player in the healthcare industry, specifically in the field of oncology. The company is known for its value-based approach, which aims to deliver better patient outcomes at a lower cost. This approach differentiates TOI from its competitors, making it a leading entity in the sector.

TOI's primary business activities revolve around managing community-based oncology practices across 15 markets and five states in the United States. The company provides a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, and innovative programs such as outpatient blood product transfusions. TOI's model is designed to provide high-quality and lower-cost care delivery through various capabilities, such as recruiting processes focused on selecting physicians who want to practice evidence-based medicine, technology-enabled care pathways ensuring adherence to evidence-based clinical protocols, strong clinical culture and physician oversight, care management to prevent unnecessary hospitalizations, and clinically appropriate integration of palliative care and hospice aligned with patients' goals of care.

The company generates revenue through its managed clinics, which are staffed with 130 oncologists and advanced practice providers. TOI's primary products and services include medical oncology services, clinical trials, and research. The customer base consists of patients covered by value-based contracts, including Medicare Advantage, Medicaid, and commercial patients.

In the realm of competition, TOI faces challenges from large and medium-sized local and national providers of cancer care services. However, the company's value-based care model and focus on delivering better patient outcomes at a lower cost set it apart from its competitors. TOI's closest competitors are traditional oncology physician practices, such as American Oncology Network, Inc., Florida Cancer Specialists & Research Institute, LLC, U.S. Oncology Network, Inc., and OneOncology, Inc. These organizations are predominantly reimbursed via FFS contracts, which can often lead to overutilization of treatments that may be medically appropriate but result in higher costs.

TOI's growth strategy involves expanding its footprint in existing markets, entering new markets, and exploring opportunities for mergers and acquisitions. The company has established relationships with major payors, including Anthem, CareMore Health, Heritage Provider Network, and Optum Care.

TOI's key offerings include medical oncology services, clinical trials, and research. The medical oncology services encompass physician services, in-house infusion and dispensary, radiation, and innovative programs such as outpatient blood product transfusions. These services are designed to provide high-quality and lower-cost care delivery.

TOI's value-based care model is a critical aspect of its business. This model is designed to deliver better patient outcomes at a lower cost. The affiliated providers focus on NCCN guideline adherence and, when possible, choose clinically equivalent but lower-cost therapeutics. This approach differentiates TOI from traditional oncology practices, which often prioritize volume over value.

Investment thesis

Bull case

The Oncology Institute’s revenue momentum is underpinned by a diversified top‑line that has consistently outpaced peers, with pharmacy and patient services each growing in double digits. The company’s pharmacy division has leveraged higher prescription volumes and script attachment to lift margin and volume, positioning it as a primary revenue driver as oncology drug pricing stabilizes. Patient services growth, driven by a mix of fee‑for‑service and delegated capitation, signals robust payer appetite for integrated oncology care, especially in high‑margin narrow‑network contracts that keep medical loss ratios in the high sixties. The company’s capital deployment strategy—an at‑the‑market equity issuance and conversion‑debt financing—has provided runway to expand pharmacy infrastructure and invest in AI, while preserving balance‑sheet strength. The projected shift to free cash flow positivity by mid‑2026 underscores a sustainable cash‑generation trajectory once the current capital expenditure cycle decelerates.
Management’s focus on MLR performance across the delegated model—reported at a mid‑seventies range—demonstrates disciplined cost control and care‑pathway adherence, key levers for margin expansion. The incremental $19 million of capitation revenue anticipated in 2025 is a direct extension of the Florida partnership with Elevance Health, which has already more than doubled its Medicare Advantage footprint, thereby scaling the company’s risk‑sharing exposure without proportionate cost growth. The ability to keep MLR stable while ramping volume indicates that the company’s risk‑sharing architecture is mature enough to absorb additional patient cohorts without margin erosion. Moreover, the partnership model allows for a capital‑efficient expansion of care sites, leveraging existing provider networks to deliver high‑quality oncology services at scale.
The planned AI deployment through the AgenTic platform is a strategic catalyst that can reduce authorization processing times from 18 minutes to five seconds, translating into an 80 percent operating expense savings per authorization and up to $2 million in annual efficiencies. By automating revenue‑cycle tasks, the company can reallocate staff to clinical roles, thereby improving patient throughput and further driving script attachment. The early demonstration of AI efficiency gains is a tangible proof point for investors, signalling that the company is on a path to operational excellence that can be replicated across other functional areas, including claims management and patient call centers. This digital transformation aligns with broader industry trends toward data‑driven care and positions the company as a technology‑enabled oncology provider.
The expansion of the Florida pharmacy into Part B specialty medication distribution represents a forward‑looking, high‑margin growth avenue that complements the core Part D dispensing strategy. By providing an in‑network specialty pharmacy option for Medicare Advantage patients, the company can capture a higher script attachment rate, directly feeding into better MLR outcomes and reinforcing the value proposition for payers. The synergy between pharmacy and patient services—especially in the context of Medicare Advantage—creates a bundled revenue model that mitigates revenue concentration risk. Furthermore, the pharmacy expansion aligns with the company’s broader strategy to diversify revenue streams beyond traditional fee‑for‑service billing, enhancing resilience against payer reimbursement volatility.
The company’s operating leverage improvement—an 820‑basis‑point swing in SG&A as a percentage of revenue—reflects disciplined cost control and a scalable business model. The reduction in SG&A to 18.5 % of revenue is achieved without compromising the expansion of oncology sites or patient services, indicating that the firm can grow revenue while keeping variable costs in check. This leverage is a critical factor in scaling to profitability, as higher revenue volumes will be absorbed by fixed costs, thereby raising profitability margins. The management’s focus on operational efficiency—through AI, pharmacy expansion, and contract negotiations—serves to amplify this leverage effect across the organization.

The Oncology Institute’s revenue momentum is underpinned by a diversified top‑line that has consistently outpaced peers, with pharmacy and patient services each growing in double digits. The company’s pharmacy division has leveraged higher prescription volumes and script attachment to lift margin and volume, positioning it as a primary revenue driver as oncology drug pricing stabilizes. Patient services growth, driven by a mix of fee‑for‑service and delegated capitation, signals robust payer appetite for integrated oncology care, especially in high‑margin narrow‑network contracts that keep medical loss ratios in the high sixties. The company’s capital deployment strategy—an at‑the‑market equity issuance and conversion‑debt financing—has provided runway to expand pharmacy infrastructure and invest in AI, while preserving balance‑sheet strength. The projected shift to free cash flow positivity by mid‑2026 underscores a sustainable cash‑generation trajectory once the current capital expenditure cycle decelerates.
Management’s focus on MLR performance across the delegated model—reported at a mid‑seventies range—demonstrates disciplined cost control and care‑pathway adherence, key levers for margin expansion. The incremental $19 million of capitation revenue anticipated in 2025 is a direct extension of the Florida partnership with Elevance Health, which has already more than doubled its Medicare Advantage footprint, thereby scaling the company’s risk‑sharing exposure without proportionate cost growth. The ability to keep MLR stable while ramping volume indicates that the company’s risk‑sharing architecture is mature enough to absorb additional patient cohorts without margin erosion. Moreover, the partnership model allows for a capital‑efficient expansion of care sites, leveraging existing provider networks to deliver high‑quality oncology services at scale.
The planned AI deployment through the AgenTic platform is a strategic catalyst that can reduce authorization processing times from 18 minutes to five seconds, translating into an 80 percent operating expense savings per authorization and up to $2 million in annual efficiencies. By automating revenue‑cycle tasks, the company can reallocate staff to clinical roles, thereby improving patient throughput and further driving script attachment. The early demonstration of AI efficiency gains is a tangible proof point for investors, signalling that the company is on a path to operational excellence that can be replicated across other functional areas, including claims management and patient call centers. This digital transformation aligns with broader industry trends toward data‑driven care and positions the company as a technology‑enabled oncology provider.
The expansion of the Florida pharmacy into Part B specialty medication distribution represents a forward‑looking, high‑margin growth avenue that complements the core Part D dispensing strategy. By providing an in‑network specialty pharmacy option for Medicare Advantage patients, the company can capture a higher script attachment rate, directly feeding into better MLR outcomes and reinforcing the value proposition for payers. The synergy between pharmacy and patient services—especially in the context of Medicare Advantage—creates a bundled revenue model that mitigates revenue concentration risk. Furthermore, the pharmacy expansion aligns with the company’s broader strategy to diversify revenue streams beyond traditional fee‑for‑service billing, enhancing resilience against payer reimbursement volatility.
The company’s operating leverage improvement—an 820‑basis‑point swing in SG&A as a percentage of revenue—reflects disciplined cost control and a scalable business model. The reduction in SG&A to 18.5 % of revenue is achieved without compromising the expansion of oncology sites or patient services, indicating that the firm can grow revenue while keeping variable costs in check. This leverage is a critical factor in scaling to profitability, as higher revenue volumes will be absorbed by fixed costs, thereby raising profitability margins. The management’s focus on operational efficiency—through AI, pharmacy expansion, and contract negotiations—serves to amplify this leverage effect across the organization.

Bear case

The company’s operating cash flow remains substantially negative—$27.8 million in Q3 2025—reflecting significant capital outlays for drug inventory and workforce expansion that are not yet offset by revenue growth. Even with an operating leverage improvement, the company’s cash burn trajectory raises concerns about liquidity, especially given that cash flow from operations could fluctuate further as drug buy‑outs intensify. If the company is unable to convert its growth into positive cash flow before 2026, it may be forced to tap additional debt or equity, potentially diluting shareholders or straining credit terms. Management’s optimistic free cash flow outlook should be viewed with caution until a clear path to consistent positive operating cash flow emerges.
The company’s $86 million of convertible debt due in 2027 represents a long‑term financing risk that could erode equity value if conversion conditions become favorable to debt holders. In a scenario where the company’s stock price remains below the conversion price, debt holders may choose to convert, diluting existing shareholders. Moreover, the debt covenant structure is not disclosed in detail; any restrictive covenants could limit management’s flexibility to pursue opportunistic growth or adjust capital structure. This fixed debt burden, coupled with the company’s current cash burn, heightens financial risk, especially if revenue growth stalls or margins compress.
The fee‑for‑service reserve of $1.8 million and the need to set such reserves signal that revenue recognition may be more conservative than the company suggests, hinting at potential receivables quality issues or higher-than-expected bad debt. The management’s justification for the reserve as a prudential measure is vague and lacks historical context, leaving room for doubt about the sustainability of fee‑for‑service income. If bad debt escalates, it could erode gross margin and push the company back into deeper losses. Investors should monitor the trend in receivable quality and reserve usage as a potential red flag.
The company’s reliance on delegated capitation contracts—while currently profitable—exposes it to payer risk and regulatory uncertainty. Payers such as Elevance Health may renegotiate or re‑price contracts as market conditions shift, especially if drug costs rise or value‑based metrics fall short of expectations. Additionally, the company’s high MLR performance in delegated models may be difficult to sustain at scale, particularly if new patient cohorts exhibit higher utilization or if payer benchmarks tighten. A decline in MLR would compress margins, undermine profitability, and erode the company’s competitive advantage.
The cybersecurity incident involving a key billing vendor, while managed quickly, exposed the company to operational disruption risk that could re‑emerge. The incident forced temporary billing outages and delayed fee‑for‑service claim submissions, illustrating a vulnerability in the company’s supply chain that could impact collections and cash flow. As the company expands its pharmacy network and increases the volume of electronic transactions, any future breach could amplify losses or create reputational harm, especially if sensitive patient data were exposed. The company must strengthen its cybersecurity posture and monitor third‑party risk to prevent repeat incidents.

The company’s operating cash flow remains substantially negative—$27.8 million in Q3 2025—reflecting significant capital outlays for drug inventory and workforce expansion that are not yet offset by revenue growth. Even with an operating leverage improvement, the company’s cash burn trajectory raises concerns about liquidity, especially given that cash flow from operations could fluctuate further as drug buy‑outs intensify. If the company is unable to convert its growth into positive cash flow before 2026, it may be forced to tap additional debt or equity, potentially diluting shareholders or straining credit terms. Management’s optimistic free cash flow outlook should be viewed with caution until a clear path to consistent positive operating cash flow emerges.
The company’s $86 million of convertible debt due in 2027 represents a long‑term financing risk that could erode equity value if conversion conditions become favorable to debt holders. In a scenario where the company’s stock price remains below the conversion price, debt holders may choose to convert, diluting existing shareholders. Moreover, the debt covenant structure is not disclosed in detail; any restrictive covenants could limit management’s flexibility to pursue opportunistic growth or adjust capital structure. This fixed debt burden, coupled with the company’s current cash burn, heightens financial risk, especially if revenue growth stalls or margins compress.
The fee‑for‑service reserve of $1.8 million and the need to set such reserves signal that revenue recognition may be more conservative than the company suggests, hinting at potential receivables quality issues or higher-than-expected bad debt. The management’s justification for the reserve as a prudential measure is vague and lacks historical context, leaving room for doubt about the sustainability of fee‑for‑service income. If bad debt escalates, it could erode gross margin and push the company back into deeper losses. Investors should monitor the trend in receivable quality and reserve usage as a potential red flag.
The company’s reliance on delegated capitation contracts—while currently profitable—exposes it to payer risk and regulatory uncertainty. Payers such as Elevance Health may renegotiate or re‑price contracts as market conditions shift, especially if drug costs rise or value‑based metrics fall short of expectations. Additionally, the company’s high MLR performance in delegated models may be difficult to sustain at scale, particularly if new patient cohorts exhibit higher utilization or if payer benchmarks tighten. A decline in MLR would compress margins, undermine profitability, and erode the company’s competitive advantage.
The cybersecurity incident involving a key billing vendor, while managed quickly, exposed the company to operational disruption risk that could re‑emerge. The incident forced temporary billing outages and delayed fee‑for‑service claim submissions, illustrating a vulnerability in the company’s supply chain that could impact collections and cash flow. As the company expands its pharmacy network and increases the volume of electronic transactions, any future breach could amplify losses or create reputational harm, especially if sensitive patient data were exposed. The company must strengthen its cybersecurity posture and monitor third‑party risk to prevent repeat incidents.

Segments Breakdown of Revenue (2024)

Long-Term Debt, Type Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	105.95 Bn	16.43	1.40	46.49 Bn
2	THC	Tenet Healthcare Corp	16.36 Bn	12.06	0.77	13.17 Bn
3	CHE	Chemed Corp	14.32 Bn	20.68	5.66	-
4	ENSG	Ensign Group, Inc	11.42 Bn	32.70	2.27	0.14 Bn
5	EHC	Encompass Health Corp	11.28 Bn	17.36	1.90	2.49 Bn
6	DVA	Davita Inc.	9.97 Bn	14.47	0.78	10.27 Bn
7	FMS	Fresenius Medical Care AG	7.30 Bn	5.68	0.37	8.49 Bn
8	OPCH	Option Care Health, Inc.	5.06 Bn	21.44	0.90	1.16 Bn

Research Tools

Oncology Institute, Inc. (NASDAQ: TOI)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2024)

Long-Term Debt, Type Breakdown of Revenue (2024)

Peer comparison

Research Tools

Oncology Institute, Inc. (NASDAQ: TOI)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2024)

Long-Term Debt, Type Breakdown of Revenue (2024)

Peer comparison

Create an account

Sign In

Reset Password